AR104807A1 - 2,5-DIALQUIL-4-H / HALO / Ether-Phenol Compounds - Google Patents

2,5-DIALQUIL-4-H / HALO / Ether-Phenol Compounds

Info

Publication number
AR104807A1
AR104807A1 ARP160101555A ARP160101555A AR104807A1 AR 104807 A1 AR104807 A1 AR 104807A1 AR P160101555 A ARP160101555 A AR P160101555A AR P160101555 A ARP160101555 A AR P160101555A AR 104807 A1 AR104807 A1 AR 104807A1
Authority
AR
Argentina
Prior art keywords
phenol
methyl
bromo
isopropyl
ethyl
Prior art date
Application number
ARP160101555A
Other languages
Spanish (es)
Inventor
Martinez Eduardo
Talley John
Kumar Mishra Rajesh
Baker Max
Original Assignee
Tansna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tansna Therapeutics Inc filed Critical Tansna Therapeutics Inc
Publication of AR104807A1 publication Critical patent/AR104807A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/04—Phenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/06—Alkylated phenols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/17—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
    • C07C39/27—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
    • C07C39/27—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms
    • C07C39/28—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms the halogen being one chlorine atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/42—Halogenated derivatives containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente divulgación provee compuestos fenólicos útiles en el tratamiento de estados clínicos neurológicos como por ejemplo convulsiones y temblores. Reivindicación 1: Un compuesto caracterizado porque se selecciona entre el grupo que consiste en: 4-bromo-5-etil-2-metil-fenol; 4-fluoro-5-isopropil-2-metil-fenol; 4-bromo-5-tert-butil-2-metil-fenol; 4-bromo-5-ciclopropil-2-metil-fenol; 4-bromo-2-etil-5-isopropil-fenol; 4-cloro-2-etil-5-isopropil-fenol; 2-etil-4-fluoro-5-isopropilo fenol; 4-bromo-5-isopropil-2-propil-fenol, 5-isopropil-2-propil-fenol; y 4-bromo-2,5-isopropil-fenol. Reivindicación 2: Un compuesto caracterizado porque se selecciona entre el grupo que consiste en: 4-bromo-2-metil-5-(2,2,2-trifluoro-1-metil-etil)-fenol; 4-bromo-5-(2-fluoro-1-metil-etil)-2-metil-fenol; 4-bromo-2-metil-5-(2,2,2-trifluoro-1-trifluorometil-etil)-fenol; 4-bromo-2-trifluorometil-5-(2,2,2-trifluoro-1-metil-etil)-fenol; 4-bromo-2-ciclopropil-5-isopropil-fenol; 4-bromo-2,5-diciclopropil-fenol; 5-isopropil-2-metil-4-trifluorometoxi-fenol; 2-ciclopropil-5-isopropil-4-trifluorometoxi-fenol; 5-ciclopropil-2-metil-4-trifluorometoxi-fenol; 2,5-diciclopropil-4-trifluorometoxi-fenol; 4-tert-butoxi-5-ciclopropil-2-metil-fenol; 4-tert-butoxi-2-ciclopropil-5-metil-fenol; 4-tert-butoxi-2,5-diciclopropil-fenol; 4-isopropoxi-5-isopropil-2-metil-fenol; 4-bromo-5-isopropil-2-trifluorometil-fenol; 4-bromo-5-(2-fluoro-1-metil-etil)-2-metil-fenol; y 4-tert-butoxi-5- isopropil-2-metil-fenol.The present disclosure provides phenolic compounds useful in the treatment of neurological clinical conditions such as seizures and tremors. Claim 1: A compound characterized in that it is selected from the group consisting of: 4-bromo-5-ethyl-2-methyl-phenol; 4-fluoro-5-isopropyl-2-methyl-phenol; 4-bromo-5-tert-butyl-2-methyl-phenol; 4-bromo-5-cyclopropyl-2-methyl-phenol; 4-bromo-2-ethyl-5-isopropyl phenol; 4-chloro-2-ethyl-5-isopropyl phenol; 2-ethyl-4-fluoro-5-isopropyl phenol; 4-bromo-5-isopropyl-2-propyl-phenol, 5-isopropyl-2-propyl-phenol; and 4-bromo-2,5-isopropyl-phenol. Claim 2: A compound characterized in that it is selected from the group consisting of: 4-bromo-2-methyl-5- (2,2,2-trifluoro-1-methyl-ethyl) -phenol; 4-Bromo-5- (2-fluoro-1-methyl-ethyl) -2-methyl-phenol; 4-Bromo-2-methyl-5- (2,2,2-trifluoro-1-trifluoromethyl-ethyl) -phenol; 4-Bromo-2-trifluoromethyl-5- (2,2,2-trifluoro-1-methyl-ethyl) -phenol; 4-bromo-2-cyclopropyl-5-isopropyl-phenol; 4-bromo-2,5-dicyclopropyl-phenol; 5-isopropyl-2-methyl-4-trifluoromethoxy-phenol; 2-cyclopropyl-5-isopropyl-4-trifluoromethoxy-phenol; 5-cyclopropyl-2-methyl-4-trifluoromethoxy-phenol; 2,5-dicyclopropyl-4-trifluoromethoxy-phenol; 4-tert-butoxy-5-cyclopropyl-2-methyl-phenol; 4-tert-butoxy-2-cyclopropyl-5-methyl-phenol; 4-tert-butoxy-2,5-dicyclopropyl-phenol; 4-isopropoxy-5-isopropyl-2-methyl-phenol; 4-bromo-5-isopropyl-2-trifluoromethyl-phenol; 4-Bromo-5- (2-fluoro-1-methyl-ethyl) -2-methyl-phenol; and 4-tert-butoxy-5- isopropyl-2-methyl-phenol.

ARP160101555A 2015-05-28 2016-05-27 2,5-DIALQUIL-4-H / HALO / Ether-Phenol Compounds AR104807A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/032876 WO2016190871A1 (en) 2015-05-28 2015-05-28 2,5-dialkyl-4-h/halo/ether-phenol compounds

Publications (1)

Publication Number Publication Date
AR104807A1 true AR104807A1 (en) 2017-08-16

Family

ID=57393569

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101555A AR104807A1 (en) 2015-05-28 2016-05-27 2,5-DIALQUIL-4-H / HALO / Ether-Phenol Compounds

Country Status (3)

Country Link
AR (1) AR104807A1 (en)
TW (1) TW201717922A (en)
WO (1) WO2016190871A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810513A (en) * 2017-01-10 2017-06-09 湖南华腾制药有限公司 A kind of preparation method of bridged piperazine derivatives
CN112812126B (en) * 2021-01-28 2022-04-05 天津全和诚科技有限责任公司 Preparation method of double-channel fluorescent probe

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723930B2 (en) * 1996-03-18 2000-09-07 Eisai R&D Management Co., Ltd. Fused-ring carboxylic acid derivatives
US7312250B2 (en) * 2002-03-12 2007-12-25 University Of Iowa Research Foundation Fluorine-substituted alkyl phenol compounds and their uses
EP1951260A4 (en) * 2005-10-21 2009-11-11 Bezwada Biomedical Llc Functionalized phenolic compounds and absorbable therefrom

Also Published As

Publication number Publication date
WO2016190871A1 (en) 2016-12-01
TW201717922A (en) 2017-06-01

Similar Documents

Publication Publication Date Title
SV2018005709A (en) 3-AZABICICLO [3.1.0] HEXANOS REPLACED AS INHIBITORS OF CETOHEXOQUINASE
CL2018000429A1 (en) Kras expression modulators
CO7111287A2 (en) Pesticide compositions and related processes
UY37134A (en) HETEROARILE COMPOUNDS AND COMPOSITIONS THAT CONTAIN USEFUL AS PAD4 INHIBITORS
CL2015003491A1 (en) Chemical compounds.
AR111986A1 (en) SUPPLEMENT AND COMPOSITION OF ANIMAL FEED
GT201300083A (en) FUNGICIDE COMPOSITIONS
ECSP10010007A (en) TREATMENT WITH LIGANDOS ALPHA-7-SELECTIVOS
CL2018000597A1 (en) Methods to treat inflammatory diseases
IN2015DN00438A (en)
BR112015028853A2 (en) DETERGENT COMPOSITION WITH LOW PH
CL2015002571A1 (en) Compositions and methods for the diagnosis and treatment of liver cancer.
BR112017028194A2 (en) diaciglycerol acyltransferase 2 modulators (dgat2)
BR112016026544A2 (en) methods to inhibit necroptosis
DOP2017000120A (en) 4-OXO-3,4-DIHIDRO-1,2,3-BENZOTRIAZINAS AS MODULATORS OF GPR139
BR112013012795B8 (en) plant products treatment process and composition
CL2018003655A1 (en) Method of manufacturing briquettes containing a calcium-magnesium compound and an iron-based compound, and briquettes thus obtained.
CL2011003211A1 (en) Fungicidal mixtures comprising azolylmethyloxyrans and another compound; compounds derived from azolylmethyloxyran; agrochemical composition; and procedure for the combat of phytopathogenic fungi.
MX2018015410A (en) Oxaborole esters and uses thereof.
IN2014DN07224A (en)
CL2012001031A1 (en) 2-Oxo-1-pyrrolidinyl-imidazothiadiazole derived compounds; pharmaceutical composition comprising them; useful for the treatment of epilepsy, neurological disorders, among others.
AR104807A1 (en) 2,5-DIALQUIL-4-H / HALO / Ether-Phenol Compounds
IN2014DN07220A (en)
WO2012170720A3 (en) Methods and compositions for treating brain cancer
EP4324477A3 (en) Oxabicycloheptanes for modulation of immune response

Legal Events

Date Code Title Description
FB Suspension of granting procedure